secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-01-17T23:59:59+00:00
Accession:  0001140361-23-001727
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Q4 revs ~$49-50M (+89% YoY), FY22 revs ~$153-154M (+90%); guides FY23 revs $210M+, first positive EBITDA in H2 2023
--------------------------------------------------------------------------------

- Q4 2022 preliminary revs ~$49-50M, up ~89% YoY; FY22 revs ~$153-154M, up ~90% over FY21.
- FY2023 revenue guidance of $210M or more, representing ~40% YoY growth.
- First-time positive EBITDA expected in second half of 2023.
- Plans to open tenth plasma collection center and obtain FDA licensure for three additional centers in 2023.
- Long-term financial targets reiterated; current trends tracking at upper bound of expectations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/0001140361-23-001727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/brhc10046612_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-001727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer